Entresto Sales Plummet, New Products Drive Strong Growth

Novartis's net sales for Q2 reached $14.4 billion, a 1% increase year-over-year, exceeding market expectations of $13.7 billion. While sales of Entresto, a key treatment for heart failure, declined by 50% to $1.18 billion due to the expiration of its U.S. patent, new drugs effectively offset this decline. Kisqali, a breast cancer treatment, Kesimpta, a treatment for multiple sclerosis, and Pluvicto, a radioligand therapy, all recorded growth of over 30%, driving overall performance. This diversified portfolio demonstrates the company's ability to withstand short-term impacts from patent expirations and contributes to stabilizing investor sentiment.

Long-Term Valuation Strategy to Overcome Approaching Patent Cliff

While short-term performance is positive, Novartis faces a significant challenge in the form of a patent cliff over the next five years. Starting with the expiration of the Entresto patent in Europe in 2028, followed by Cosentyx, the top-selling treatment for plaque psoriasis, in the U.S. in 2029. Furthermore, the patents for Kesimpta and Kisqali, current growth drivers, will expire in 2031, making it crucial to strengthen the pipeline to prepare for a long-term decline in sales. Consequently, global investors are evaluating Novartis's long-term corporate value based on the success of upcoming major clinical data releases rather than current financial performance.

Securing Next-Generation RNA Platform Through $12 Billion Acquisition of Avidity

To strengthen its pipeline, Novartis completed the acquisition of Avidity Biosciences, an RNA therapeutics company, for $12 billion in February. This acquisition provides Novartis with access to Antibody Oligonucleotide Conjugate (AOC) technology targeting myotonic dystrophy type 1 (DM1), a rare muscular disease. In particular, del-desiran, a key candidate acquired through this deal, is generating significant interest due to its innovative mechanism of action, which removes toxic DMPK mRNA. The results of the ongoing global Phase 3 trial (HARBOR) are expected to be announced this year, and the success of this data will be a critical milestone in determining Novartis's future presence in the rare disease market.

Awaiting Key Pipeline Data for Pelacarsen and Remibrutinib in the Second Half of the Year

Another clinical trial result that will attract market attention in the second half of the year is the Phase 3 trial of pelacarsen, a treatment for hypercholesterolemia, co-developed with Ionis Pharmaceuticals. The results of the Lp(a)HORIZON trial, which evaluates the cardiovascular risk reduction effect of pelacarsen, are expected to demonstrate the potential for a new standard of care. In addition, clinical data for remibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor targeting autoimmune diseases and multiple sclerosis, are also awaited. If these multiple Phase 3 trials are successful, Novartis will be able to alleviate concerns about patent expirations and solidify its leading position in the next-generation therapeutics market.